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Key points
† Monitoring whole-blood
coagulation using
viscoelasticity assays is
useful in managing
perioperative bleeding.
† This observational study
compared
thromboelastometry
[ROTEMw] assays with
standard coagulation
tests in 359 children in six
age groups.
† Age-dependent
differences identified in
both standard and
ROTEMw assays provide
important reference
ranges for monitoring
paediatric surgical
patients.
Background. The small sample volume needed and the prompt availability of results make
viscoelastic methods like rotational thromboelastometry (ROTEMw) attractive for
monitoring coagulation in small children. However, data on reference ranges for ROTEMw
parameters in children are scarce.
Methods. Four hundred and seven children (ASA I and II) undergoing elective surgery were
recruited for this prospective, two-centre, observational study. Subjects were grouped as
follows: 0–3, 4–12, 13–24 months, 2–5, 6–10, and 11–16 yr. Study objectives were to
establish age-dependent reference ranges for ROTEMw assays, analyse age dependence
of parameters, and compare ROTEMw data with standard coagulation tests.
Results. Data from 359 subjects remained for final analysis. Except for extrinsically
activated clot strength and lysis, parameters for ROTEMw assays were significantly
different among all age groups. The most striking finding was that subjects aged 0–3
months exhibited accelerated initiation (ExTEM coagulation time: median 48 s, Q1–Q3
38–65 s; P¼0.001) and propagation of coagulation (a angle: median 78o, Q1–Q3 69–
84o; P,0.001) and maximum clot firmness (median 62 mm, Q1–Q3 54–74 mm),
although standard plasma coagulation test results were prolonged (prothrombin time:
median 13.2 s, Q1–Q3 12.6–13.6 s; activated partial thromboplastin time: median 42 s,
Q1–Q3 40–46 s). Lysis indices of ,85% were observed in nearly one-third of all children
without increased bleeding tendency. Platelet count and fibrinogen levels correlated
significantly with clot strength, and fibrinogen levels correlated with fibrin polymerization.
Conclusions. Reference ranges for ROTEMw assays were determined for all paediatric age
groups. These values will be helpful when monitoring paediatric patients and in studies
of perioperative coagulation in children.
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Viscoelastic coagulation tests have gained a renewed inter-
est in the safe management of surgery- or trauma-induced
coagulopathy in adult and paediatric patients.1 – 4 Visco-
elastic whole-blood analyses, such as thromboelastography
(TEGw) and thromboelastometry (ROTEMw), reflect initiation
and propagation of coagulation, fibrinogen/fibrin–platelet
interaction, and clot lysis. In 1997, the ROTEMw device was
introduced into clinical routine at our institution. A multi-
centre study published by Lang and colleagues5 presented
reference ranges for ROTEMw assays for adults aged 17–85
yr. With the exception of some data referring to preterm
neonates, newborns, and children exhibiting cardiac failure,
reference data are scarce for paediatric patients.6 – 10
The main objective of our study was to investigate refer-
ence ranges for ROTEMw assays in a representative group
of normal children undergoing elective surgery encompass-
ing all paediatric age groups. Because platelet number, fibri-
nogen concentration, and coagulation factor XIII (FXIII)
contribute particularly to the clinically relevant parameter
clot strength, these parameters were analysed in addition
to conducting standard coagulation tests and ROTEMw
assays.
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Methods
Study protocol
The study was conducted at two tertiary care hospitals.
Innsbruck Medical University Hospital performs 35 000
anaesthesia procedures per year. After 1 yr of recruitment,
a second study site, Zurich University Children’s Hospital,
which performs about 7000 anaesthesia procedures per
year, was included to facilitate recruitment within an accep-
table time period.
The study was approved by the institutional Ethics Commit-
tee at each hospital. After written informed consent was
received from parents for blood sampling, a total of 407 chil-
dren (ASA physical status I–II) aged 0–16 yr who were under-
going minor surgery were enrolled in this prospective study.
Inclusion criteria were elective surgical procedures requir-
ing placement of an i.v. catheter. Exclusion criteria were tech-
nical problems encountered in blood sampling, prematurity,
age above 16 yr, known haematological disease, emergency
surgery, acute systemic infection, known history of congenital
or acquired coagulopathy including renal, hepatic, and bone
marrow disease, any medication interfering with haemostasis,
and cardiac disease. A standardized bleeding history was
obtained based on the recommendation of the task force on
perioperative coagulation by OEGARI (www.oegari.at/
dateiarchiv/205/guidelines english version.pdf).
Age groups were defined according to the studies by Chan
and colleagues11 observing children ,1 to 16 yr and the
study of Andrew and colleagues12 showing haemostatic matu-
ration, especially during the first 3 months after birth. Six age
groups were defined as follows: 0–3, 4–12, 13–24 months,
2–5, 6–10, and 11–16 yr. The scheduled group size was at
least 50 children according to the National Committee for
Clinical Laboratory Standards (NCCLS) guidelines for establish-
ing reference ranges.13 Since the drop-out rate was expected
to be high because of difficulties in blood sampling or
because baseline laboratory test results were outside the
reference range, a total of 407 children had to be recruited.
Routine patient management
All children were fasted until 4 h (,1 yr) or 6 h (.1 yr) before
surgery and those who were older than 5 months received
midazolam 0.5 mg kg21 orally 30–45 min or rectally 15–20
min before anaesthesia. Anaesthesia was induced by inhala-
tion administration of sevoflurane in oxygen or i.v. by injec-
tion of fentanyl or alfentanyl and propofol. Anaesthesia
was then continued using either propofol or sevoflurane in
oxygen/air or oxygen/nitrous oxide mixture, fentanyl or remi-
fentanil, and rocuronium or atracurium according to the
planned surgical procedure.
Blood sampling
Using an 18, 20, 22, or 24 G catheter, blood samples were
immediately obtained with a light tourniquet used to
prevent blood stasis. If blood samples were drawn from
already established i.v. lines, the first 2 ml of blood was
discarded. Blood samples were collected in 1.2 ml tubes con-
taining 1.6 mg EDTA ml21 blood (Sarstedt, Nuembrecht,
Germany) for measuring blood count and two 1.4 ml tubes
containing 0.14 ml citrate solution (0.106 mol litre21 trisodium
citrate solution) (Sarstedt) for analysing concentrations of
FXIII, performing standard coagulation tests [prothrombin
time (PT), activated partial thromboplastin time (aPTT), antith-
rombin, and fibrinogen concentration] and ROTEMw tests.
Laboratory analyses
Standard coagulation parameters were determined with the
following assays (all reagents manufactured by Siemens
Healthcare AG, Erlangen, Germany): PT (Thromborel Sw),
aPTT (Pathromtin SLw), antithrombin (Berichromw Antithrom-
bin III), fibrinogen concentration (Multifebrenw), and FXIII
(Berichromw).
ROTEMw
Technical details on the ROTEMw device are presented
elsewhere.1
ROTEMw analyses were performed within 10 min after blood
withdrawal by four anaesthetists highly experienced with
ROTEMw analyses as bedside tests (Innsbruck Medical Univer-
sity) or by specialized laboratory personnel from the Central
Laboratory (Zurich University Children’s Hospital), all using orig-
inal reagents purchased from Pentapharm, Munich, Germany.
Defined standard operating procedures included warming
sampling tubes to 378C and gently inverting these three
times to re-suspend any sediment before starting analysis.
According to the manufacturer’s instructions, extrinsically acti-
vated (ExTEM), intrinsically activated (InTEM), and fibrinogen
polymerization (FibTEM) tests were performed. Data were col-
lected for 60 min, and the ROTEMw parameters coagulation
time (CT, s), clot formation time (CFT, s), a angle (ALP, 8), ampli-
tude recorded at 10 min (A10), and maximum clot firmness
(MCF, mm) were registered (Fig. 1). The clot lysis index after
60 min (CLI60, %) describes the ratio between the MCF and
amplitude at 60 min. To assess fibrin polymerization, the rel-
evant parameters A10 and MCF were analysed.
In addition, an ApTEM test (aprotinin-containing extrinsi-
cally activated test) was performed in the last 196 children
if signs of fibrinolysis were detected.
Data analysis
The primary study objective was to estimate reference
ranges for standard ROTEMw assays in the six age groups.
Secondary study endpoints were to (i) search for possible
differences between age groups, (ii) analyse gender-related
differences, (iii) compare ROTEMw parameters with standard
coagulation tests and concentrations of FXIII, and (iv)
compare clot strength at 10 min (A10) with MCF.
The SPSS software package (Version 18.0; SPSS Inc.,
Chicago, IL, USA) was used for statistical analyses. Descrip-
tive methods were used to calculate the 2.5% and 97.5%
percentiles according to the NCCLS guidelines for establish-
ing reference ranges.13 Data are presented as median
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values with Q1 and Q3 quartiles, if not otherwise indicated.
The Kolmogorov–Smirnov test was applied to test for Gaus-
sian distribution of study variables. Since several parameters
investigated showed statistically significant departure from
normality (at an a level of 0.05), the non-parametric
Kruskal–Wallis test, the Mann–Whitney U-test (to investigate
age- and gender-related differences), and the Spearman cor-
relation were used for analysis. Owing to multiple testing,
Bonferroni’s adjustment was applied with a more conserva-
tive level of significance set at ,0.005.
Results
Study population
A total of 407 subjects were recruited; 48 were excluded post
hoc because of difficulties in blood sampling or because stan-
dard laboratory test results were outside the reference ranges,
leaving 359 subjects (325 Innsbruck and 34 Zurich) eligible for
analysis. Each age group encompassed at least 50 children.
Demographic data are listed in Table 1. Included subjects
underwent the following types of surgery: general (n¼214),
orthopaedic (n¼43), plastic (n¼53), removal of osteosynth-
esis material (n¼11), ear, nose, and throat (n¼3),
ophthalmological (n¼5), urological (n¼21), and dental
(n¼9). Data on standard laboratory parameters and concen-
trations of FXIII are given in Table 2.
Intrinsically activated ROTEMw assay
All parameters of the intrinsically activated assay differed
significantly among all age groups (Table 3 and Fig. 2). CT
range was wider than reported for adults, and highest
values were observed in children aged 0–3 months
(P¼0.001). CFT was shortest (P,0.001) and a angle
(P,0.001) and MCF (P,0.001) strongest in children aged
0–3 months when compared with children .3 months.
A10 strongly correlated (correlation coefficient 0.95;
P,0.001) with MCF, with the median difference being 1.5
mm (inter-quartile range 3–5 mm).
Extrinsically activated ROTEMw assay
CT, CFT, and a angle differed significantly, whereas MCF and
CLI60 were comparable among all age groups (Table 3 and
Fig. 3). CT was shortest in children 0–3 months (P,0.001),
CFT was shortest (P,0.001), and a angle (P,0.001) and
MCF showed highest degrees in children 0–3 months. A10
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Fig 1 Representative thromboelastometric tracing (ROTEMw) showing the dynamics of initiation of coagulation (CT), propagation of coagu-
lation (CFT and ALP), maximum clot firmness (MCF), and clot lysis index (CLI).
Table 1 Demographics of paediatric age groups (median and inter-quartile range)
Age group n Age Sex (n) (male, female) Height (cm) Body weight (kg)
0–3 months 51 1.0 (1.0–2.0) months 39, 12 56.0 (53.0–59.0) 5.0 (4.2–5.5)
4–12 months 55 7.0 (6.0–10.0) months 38, 17 70.0 (66.0–75.5) 8.3 (7.2–9.4)
13–24 months 54 18.0 (15.8–20.0) months 42, 12 81.0 (75.8–85.0) 11.0 (9.9–12.0)
2–5 yr 70 3.3 (2.6–4.3) yr 52, 18 103.5 (92.8–108.5) 15.0 (13.4–17.0)
6–10 yr 79 7.3 (6.0–9.3) yr 59, 20 128.0 (116.8–136.5) 24.3 (20.0–30.0)
11–16 yr 50 13.7 (11.8–14.9) yr 30, 20 158.0 (147.5–167.8) 52.0 (41.5–69.5)
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strongly correlated with MCF (correlation coefficient 0.91;
P,0.001) and the median difference was 2 mm (inter-
quartile range 2–5 mm).
Eighty-six subjects showed CLI60,85%, and 27 subjects
even showed values ,80%. In 27 subjects with enhanced
lysis, an ApTEM test was available showing improved lysis
Table 2 Median and first and third quartiles of cell count and coagulation parameters. aPTT, activated partial thromboplastin time; PT,
prothrombin time; AT, antithrombin; FXIII, coagulation factor XIII; Hb, haemoglobin (n¼359)
n aPTT (s) PT (s) AT (%) Fibrinogen
(mg dl21)
FXIII (%) Hb (g dl21) Platelets
(3106 litre21)
Reference ranges in adults
(Central Lab)
26–37 11.4–14.0 75–125 210–400 70–140 13.0–17.7 150–380
0–3 months [median
(Q1–Q3)]
51 42 (40–46) 13.2 (12.6–13.6) 70 (63–78) 228 (206–251) 92 (81–101) 10.2 (9.4–10.8) 402 (312–445)
4–12 months [median
(Q1–Q3)]
55 37 (33–40) 12.8 (12.1–13.6) 94 (87–100) 235 (196–264) 88 (76–99) 11.1 (10.4–11.6) 339 (288–425)
13–24 months [median
(Q1–Q3)]
54 34 (32–37) 12.4 (12.0–13.1) 100 (95–107) 253 (224–307) 90 (80–104) 11.6 (11.2–12.4) 312 (244–357)
2–5 yr [median (Q1–Q3)] 70 34 (32–36) 12.7 (12.2–13.4) 98 (92–103) 273 (249–325) 93 (81–105) 11.9 (11.4–12.3) 294 (274–363)
6–10 yr [median (Q1–Q3)] 79 34 (31–35) 12.7 (12.2–13.1) 95 (90–100) 262 (240–310) 88 (80–99) 12.8 (12.2–13.4) 270 (239–311)
11–16 yr [median (Q1–Q3)] 50 32 (31–35) 12.6 (12.0–13.2) 97 (88–103) 274 (239–359) 89 (82–106) 13.9 (13.2–14.9) 262 (239–283)
Table 3 Median and reference ranges (2.5% and 97.5% percentiles) for ROTEMw InTEM and ExTEM assay. CT, coagulation time; CFT, clot
formation time; ALP, a angle; A10, clot strength at 10 min; MCF, maximum clot firmness; CLI60, clot lysis index at 60 min. The Kruskal–Wallis test
showed overall age-related differences for InTEM CT (P¼0.002), CFT, ALP, A10, and MCF (all P,0.001), but no differences for ExTEM MCF or ExTEM
CLI60 (n¼359)
ROTEMw
parameter
InTEM CT
(s)
InTEM
CFT (s)
InTEM
ALP (8)
InTEM
A10 (mm)
InTEM
MCF (mm)
ExTEM
CT (s)
ExTEM
CFT (s)
ExTEM
ALP (8)
ExTEM
A10 (mm)
ExTEM
MCF (mm)
ExTEM
CLI60 (%)
Median 184 63 77 55 61 55 95 72 53 60 No data
Reference ranges
in adults5
137–246 40–100 71–82 44–68 52–72 42–74 46–148 63–81 43–65 49–71
0–3 months (n¼51)
Median 184 44 81 62 66 48 57 78 60 62 87
Reference
range
105–285 27–88 74–85 50–72 54–73 38–65 30–105 69–84 51–72 54–74 71–94
4–12 months (n¼55)
Median 172 60 78 59 63 53 72 76 57 60 86
Reference
range
76–239 37–100 73–83 47–70 52–73 37–77 44–146 68–82 46–68 46–71 71–95
13–24 months (n¼54)
Median 161 61 78 59 64 55 75 75 56 60 88
Reference
range
99–207 42–112 70–82 45–67 50–72 37–73 46–139 64–81 41–68 46–72 77–94
2–5 yr (n¼70)
Median 170 60 78 59 63 56 72 75 58 61 86
Reference
range
99–239 40–94 72–82 49–68 53–73 46–97 41–109 69–82 49–68 52–70 74–93
6–10 yr (n¼79)
Median 168 64 77 57 62 57 77 74 56 60 87
Reference
range
97–212 48–93 72–80 49–66 53–69 43–74 49–114 67–80 49–65 53–68 70–97
11–16 yr (n¼50)
Median 171 68 77 56 62 59 81 74 57 62 88
Reference
range
128–206 45–106 70–81 48–67 54–71 44–91 53–115 67–80 49–67 53–72 76–94
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index in 12 (data not shown). In subjects exhibiting
enhanced fibrinolysis, FXIII levels were within reference
ranges [88% (inter-quartile range 80–97%)].
Fibrinogen/fibrin polymerization
Results for fibrinogen/fibrin polymerization differed signifi-
cantly among all age groups (Table 4), with lowest 2.5%
percentiles observed in children aged 13–24 months. A10
strongly correlated with MCF (correlation coefficient 0.98;
P,0.001), the difference being 0.6 mm (inter-quartile range
0–1 mm).
Correlation between ROTEMw parameters and
standard laboratory tests and FXIII levels
For the entire study population, aPTT values correlated weakly
(correlation coefficient 0.34; P,0.001) with intrinsically acti-
vated CT, whereas no correlation was found between PT and
extrinsically activated CT. FXIII, fibrinogen concentration,
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Fig 2 ROTEMw InTEM reference ranges and median of all age groups and adults showing maturation of CT, CFT, and MCF. *P,0.005 vs children
.3 months; #P,0.005 vs children ,11 yr.
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Fig 3 ROTEMw ExTEM reference ranges and median of all age groups and adults showing maturation of CT, CFT, and MCF. *P,0.005 vs children
.3 months; #P,0.005 vs children ,11 yr.
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and platelet count showed stronger correlations with MCF
(correlation coefficient FXIII ,0.4; fibrinogen and ExTEM
MCF 0.52, and platelets and InTEM MCF 0.592; P,0.001) and
fibrinogen concentrations significantly correlated with MCF
(correlation coefficient FibTEM MCF 0.52; all P,0.001), which
was also observed in children aged under 12 months (corre-
lation coefficient FibTEM MCF 0.50; P¼0.001). Children aged
0–3 months showed the lowest median levels of AT and
highest platelet count. Both AT and platelet count showed
no correlation with CTs, but platelet count showed significant
correlation with accelerated clot formation (CFT: correlation
coefficient 20.507, P,0.001; a angle: correlation coefficient
0.477, P,0.001) and MCF (correlation coefficient 0.535;
P,0.001). We found no correlation between haemoglobin
values and any ROTEMw parameter.
Gender dependency of ROTEMw parameters
in children
Although no exact balance between male and female chil-
dren was established, no sex-related differences in ROTEMw
parameters were observed (data not shown).
Discussion
Investigating a large cohort of otherwise healthy children, we
found that the ROTEMw parameters measuring initiation and
propagation of coagulation and fibrinogen/fibrin polymerization
showed significant age dependency, whereas extrinsically
activated clot firmness and fibrinolysis were similar among all
age groups.
The most striking finding was that children aged 0–3
months, despite showing prolonged standard plasma coagu-
lation test results, exhibited accelerated coagulation and
strong clot firmness. Coagulation factors are independently
synthesized by the fetus, and newborns show concentrations
of factors II, VII, IX, X, XI, and XII below adult values, whereas
concentrations of fibrinogen, factors V, VIII, XIII, and the von
Willebrand factor are within the range of or above adult
values.14 15 The fetal fibrinogen molecule differs from that
of the adult by exhibiting fewer fractions of high molecular
fibrinogen, and increased content of sialic acid and phos-
phorus.16–18 In addition, concentrations of antithrombin and
protein C are lower than in adults, whereas levels of a1 anti-
plasmin, C1 esterase inhibitor, and a2 macroglobulin are
above those of adults.14 15 Consequently, standard coagu-
lation tests, which strongly depend on concentrations of pro-
coagulant proteins, are prolonged in early childhood, although
healthy newborns show no increase in bleeding tendency. In
contrast, and as also observed by others,19 viscoelastic whole-
blood analyses showed accelerated initiation of coagulation
after extrinsic activation and enhanced propagation of coagu-
lation, whereas clot strength was within the range of adults.
In the youngest age group, intrinsically activated parameters
also showed a higher upper limit of the reference range for
initiation of coagulation, clot formation was accelerated, as
in extrinsically activated assays, and median clot firmness
was even stronger than that reported for adults. To ensure
that findings were not influenced by the physiologically low
haemoglobin level in the youngest age group, we looked for
relationships between haemoglobin and ROTEM parameters,
but found no significant correlation.
It was not clear why in the youngest age group activation
by the intrinsic pathway (InTEM) showed prolonged CTs, but
the shortest CTs were observed in the ExTEM assay. As no
correlation was found between CT and platelet count or
between CT and antithrombin, other factors, such as a
slower onset of maturation of contact activators (FXI and
FXII) when compared with a faster maturation of FVII,
might be responsible for this observation.
Differences in study design and reagents used make a
direct comparison of our results with those of other studies
somewhat difficult. Using either modified ROTEMw or TEGw
analysis in term and preterm infants, three other studies
reported data similar to ours.6 9 10 Haizinger and colleagues7
and Osthaus and colleagues8 used standard ROTEMw assays
showing ROTEMw parameters in the range observed in the
present study, although their age groups differed. Edwards
and colleagues9 performed classical TEGw in neonates and
reported shorter r times (corresponding to ROTEMw CT), but
also reduced clot firmness in neonates.20 In contrast,
another study using kaolin-activated TEGw to investigate
children between 1 month and 16 yr found no relation with
age,11 whereas Miller and colleagues21 using native TEGw
also found shorter r times and k values (corresponding to
ROTEMw CFT) below 12 months when compared with those
Table 4 Median and reference ranges (2.5% and 97.5%
percentiles) for ROTEMw FibTEM assay. A10, clot strength at 10
min; MCF, maximum clot firmness. The Kruskal–Wallis test
showed overall age-related differences for A10 (P¼0.03) and MCF
(P¼0.042) (n¼355)
ROTEMw parameter A10 (mm) MCF (mm)
Median 14 16
Reference ranges in adults5 9–24 9–25
0–3 months (n¼51)
Median 13 14
Reference range 8–22 8–23
4–12 months (n¼53)
Median 12 12
Reference range 6–24 7–25
13–24 months (n¼52)
Median 11 12
Reference range 5–24 6–24
2–5 yr (n¼70)
Median 12 13
Reference range 7–22 7–23
6–10 yr (n¼79)
Median 11 12
Reference range 7–21 7–22
11–16 yr (n¼50)
Median 12 13
Reference range 7–22 8–24
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of older children and adults. Cvirn and colleagues10 also
measured the endogenous thrombin potential in cord blood
and showed shorter lag times for thrombin generation,
thereby confirming the ROTEMw/TEGw results with regard to
faster initiation of coagulation.
PT and aPTT values showed only weak or no correlation
with ROTEMw CTs. A similar finding was also reported in
orthopaedic patients showing decreased levels of coagu-
lation factors during haemodilution4 and during liver trans-
plantation.22 Sufficient clot firmness is a prerequisite for
cessation of bleeding from wound sites and microvessels.
For example, clot firmness is massively reduced in Glanz-
mann’s thrombasthenia23 and in congenital fibrinogen
deficiency,24 and these patients show increased bleeding
tendency even without exposure to surgical stress.
Strauss and colleagues6 demonstrated that clot firmness
correlates with gestational age, reaching median levels of
60 mm in full-term neonates, which is in perfect concor-
dance with our findings. In addition, we demonstrate that
children aged 4–24 months showed the lowest 2.5% percen-
tiles for clot strength, indicating low reserve when exposed to
haemodilution and blood loss. We also show that the ampli-
tude measured at 10 min highly significantly correlated with
final clot firmness. Thus, data obtained at 10 min might be
suitable as a means of guiding therapy. In our study, ampli-
tude of fibrin/fibrinogen polymerization as measured with a
cytochalasin D-containing assay (FibTEM) differed among
age groups, and some children aged ,24 months showed
low 2.5% percentiles, thereby explaining the low total clot
firmness. In addition, fibrinogen concentrations correlated
significantly with fibrin polymerization and total clot
strength, also in the group of children younger than 12
months, whereas Miller and colleagues25 using TEGw and
abciximab found no such correlations. The reason for these
contrasting results is not entirely clear, but might be
related to the different types of assays.
Two other studies in 59 healthy newborns and 100
healthy children showed no enhanced fibrinolytic activity in
children.9 11 As in the present study and without relation to
bleeding tendency, Miller and colleagues21 observed that low
clot lysis indices (,85%), usually interpreted as hyperfibrinoly-
sis, frequently occur in children.21 26 Fibrinolysis as measured
with ROTEMw has been shown to correlate with levels of
tissue plasminogen activator and also factor XIII concen-
trations.27 28 Although we did not analyse molecular markers
of fibrinolysis in the present study, factor XIII levels were com-
parable in children with and without enhanced fibrinolysis. We
speculate that the observed reduction in clot firmness may
result from enhanced contraction of formed clots, namely in
those cases showing identical indices after addition of aproti-
nin. This hypothesis, however, needs to be confirmed by
further investigations.
In adults, ROTEMw assays showed a slight trend towards
faster coagulation activation and clot strength in females.5
When compared with male newborns, significantly higher
levels of coagulation factor VII were reported in female new-
borns, who also showed a trend to increased levels of
coagulation factor VIII.29 However, confirming other data,
we found no gender-related changes in ROTEMw parameters
during childhood.9
Excluding all children ,4 months, overall Kruskal–Wallis’s
test revealed no significant changes for all ROTEMw
parameters.
Limitations of our study need to be considered. Adequate
blood sampling can be cumbersome in small children. Great
care was taken to avoid the known influences of pre-analytic
factors. Nevertheless, the i.v. catheters used needed to be
small in size. Thus, a degree of artificial coagulation acti-
vation cannot be excluded. However, our findings on acceler-
ated coagulation in the youngest age groups conform to the
described physiology of haemostasis in childhood and agree
with results obtained in other studies.6 9 10 15 The finding that
fibrinogen levels correlate with fibrin polymerization and clot
firmness is of clinical importance, because reduced clot firm-
ness in the presence of microvascular bleeding usually trig-
gers substitution therapy. However, these correlations can
be altered in disease and during haemodilution. It is well
known that measurements of fibrinogen concentration are
overestimated in the presence of colloids30 and that fibrino-
gen/fibrin polymerization depends on various factors that are
not reflected by measuring fibrinogen concentration.31 – 34
Critics may argue that our results might be influenced by
the fact that blood samples were drawn after induction of
anaesthesia, and preoperative fluid deficit might be a poten-
tial confounding factor. However, the majority of blood col-
lections were performed immediately after inhalation
induction of anaesthesia and children were also allowed to
receive clear fluids up to 2 h before surgery. Available data
show that propofol, fentanyl, and sevoflurane exhibit no
effect on platelets.35 Thus, we believe that the remaining
influences on test results should be rather small.
In conclusion, we show that reference ranges for ROTEMw
parameters in children are age-dependent. We also show
that, similar to adults, in children, fibrinogen concentrations,
platelet count, and FXIII contribute to clot firmness as
measured with ROTEMw assays. The strong association
between the 10 min value for clot firmness and final
results at 60 min allows rapid diagnosis and treatment.
Because age dependency of clinically relevant ROTEMw par-
ameters was most obvious in children 0–3 and 4–24
months, we suggest that institutional age-related reference
ranges be defined, at least for these groups of children.
Although initiation of coagulation in children ,3 months
analysed with standard plasma coagulation test was pro-
longed, ROTEMw showed accelerated clot formation and
strong clot firmness, which might be partly attributed to
increased platelet count. The results of this study should be
helpful in understanding developmental haemostasis and
facilitating haemostasis management in children.
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